The Role for Clinical Translational Pharmacology in Advancing Pharmacoequity

Advancing pharmacoequity is both a public health imperative and a scientific opportunity. While policy efforts have focused largely on post-approval issues like pricing, insurance, evidence-based prescribing practices, and pharmacy access, science offers powerful tools to address inequities much earlier. This perspective outlines how clinical translational pharmacology (CTP) is uniquely positioned as a scientific discipline to advance pharmacoequity through its principles, innovation, methods, and patient-centered applications across the discovery, development, regulation, and utilization (DDRU) continuum.